Open AccessFACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY
Author(s) -
Chiharu Iwahashi,
Shoko Utamura,
Kazuki Kuniyoshi,
Koji Sugioka,
Yuhei Konishi,
Norihisa Wada,
Shunji Kusaka
Publication year - 2021
Publication title -
retina
Language(s) - English
Resource type - Journals
eISSN - 1539-2864
pISSN - 0275-004X
DOI - 10.1097/iae.0000000000003196
Subject(s) - retinopathy of prematurity , ranibizumab , medicine , bevacizumab , ophthalmology , vascular endothelial growth factor , vegf receptors , logistic regression , gestational age , chemotherapy , pregnancy , biology , genetics
To investigate the efficacy and risk factors of intravitreal antivascular endothelial growth factor injection (anti-VEGF therapy) for retinopathy of prematurity (ROP).